Mathematical modeling for the combination treatment of IFN- and anti-PD-1 in cancer immunotherapy
From MaRDI portal
Publication:2103601
DOI10.1016/J.MBS.2022.108911zbMATH Open1505.92103OpenAlexW4296769722MaRDI QIDQ2103601FDOQ2103601
Authors: Kang-Ling Liao, Kenton D. Watt
Publication date: 9 December 2022
Published in: Mathematical Biosciences (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.mbs.2022.108911
Recommendations
- Combination therapy for cancer with IL-27 and anti-PD-1: A simplified mathematical model
- Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: a mathematical model
- Mathematical modeling of an immune checkpoint inhibitor and its synergy with an immunostimulant
- A mathematical model of tumor-immune interactions with an immune checkpoint inhibitor
- Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor
Medical applications (general) (92C50) PDEs in connection with biology, chemistry and other natural sciences (35Q92)
Cites Work
- A methodology for performing global uncertainty and sensitivity analysis in systems biology
- Modeling the inhibition of breast cancer growth by GM-CSF
- Modelling the interactions between tumour cells and a blood vessel in a microenvironment within a vascular tumour
- A mathematical model of tumor-immune interactions
- Title not available (Why is that?)
- The role of exosomes in pancreatic cancer microenvironment
- Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor
Cited In (17)
- Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor
- Mathematical modeling and analysis of CD200-CD200R in cancer treatment
- Dynamic analysis of a drug resistance evolution model with nonlinear immune response
- Mathematical modeling and analysis of cancer treatment with radiation and anti-PD-L1
- Mathematical modeling of tumor immune interactions: the role of anti-FGFR and anti-PD-1 in the combination therapy
- A mathematical model of tumor-immune interactions with an immune checkpoint inhibitor
- Combination therapy for cancer with IL-27 and anti-PD-1: A simplified mathematical model
- A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer
- IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer
- B7-H1 and a mathematical model for cytotoxic T cell and tumor cell interaction
- Different mechanisms of CD200-CD200R induce diverse outcomes in cancer treatment
- Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: a mathematical model
- Modeling LSD1-mediated tumor stagnation
- Antagonism and negative side-effects in combination therapy for cancer
- Targeting CD4+ T cell exhaustion to improve future immunotherapy strategies
- Computational modeling and experimental investigations to enhance the successful response of anti-PD-\(1\) cancer immunotherapies
- THE EFFECT OF LENVATINIB AND PEMBROLIZUMAB ON THYROID CANCER REFRACTORY TO IODINE 131I SIMULATED BY MATHEMATICAL MODELING
This page was built for publication: Mathematical modeling for the combination treatment of IFN-\(\gamma\) and anti-PD-1 in cancer immunotherapy
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2103601)